Thanks for posting GAC. Not discussed here, but was aware of the news. I post occasionally about ESPR over on Stockhouse, but it's pretty lonely over there. Not a bad deal for a drug (bempedoic acid) that hasn't yet passed a CVOT (reads out 2022) and that will only be initially marketed for LDL-C lowering in an already crowded market (statins, ezetimibe, PCSK9s) until CVOT reads out. 

Just think what kind of deals apabetalone would be worth if it passes its BETonMACE CVOT with flying colors! 

BDAZ